Bleeding
Conditions
Brief summary
The investigators primary objective is to compare the effectiveness of epsilon-aminocaproic acid (EACA) and tranexamic acid (TA) in reducing bleeding and transfusion in cardiac surgery, with the hypothesis that TA is more effective. The investigators also seek to further examine the clinical benefits and adverse effects profiles of epsilon-aminocaproic acid and tranexamic acid.
Detailed description
This is a single center double blinded randomized controlled study comparing the effectiveness of epsilon-aminocaproic acid (EACA) and tranexamic acid (TA) in reducing 24hour blood transfusion and chest tube drainage. From October 2008 to September 2011, patients greater than 18 years of age, scheduled for cardiac surgery requiring CPB were consented. Eligible operations included; coronary artery bypass graft surgery (CABG), a heart valve repair/replacement, or a concomitant CABG and valve surgery were enrolled. Consented patients were randomized into one of the two groups using a 1:1 randomization sequence generated by a computer program. Randomization sequence and the study drugs were kept in a locked box and were opened only by unblinded study personnel who were not involved in the clinical care of the patient. This person prepared the study drug following the instructions of the study protocol, resulting in preparations of EACA and TA that contained equi-potent similar volumes of the drug in the syringe, in order to ensure blinding. Antifibrinolytic study drug was administered following anesthetic induction. EACA was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. TA was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in the investigators hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin. The primary endpoint was the amount of chest tube drainage and the amount of blood products used in the first 24 hours following surgery (surrogate measurement for blood loss) was measured at 4, 8, 12 and 24 hours after surgery. The incidence of packed red blood cells (PRBC), fresh frozen plasma (FFP), cryoprecipitate and platelets administered during the first 24 hours after surgery was collected. Additionally, patients were monitored for any complications during their stay in the hospital and up to 30 days post-operatively. Complications included renal dysfunction (defined as the need for at least 1 hemodialysis or doubling of pre-surgical creatinine levels), stroke and seizures (clinically diagnosed), myocardial infarction (new Q waves in two electrocardiogram leads), cardiac arrest, respiratory failure, re-operation and death. Monitoring of the patients prior to discharge involved chart review during their stay in the hospital; if a post-operative complication was suspected, the complication was confirmed using Montefiore Medical Center's Carecast Database, which contained independent results such as MRI's, CT scans, or labs. Additionally, computer records of the patients were searched to determine if there were documented complications in the 30-day post-operative time period.
Interventions
Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
Sponsors
Study design
Eligibility
Inclusion criteria
* Informed consent obtained before any trial-related activities * Subjects scheduled to undergo cardiac surgery requiring cardiopulmonary bypass
Exclusion criteria
* Vulnerable patient populations (unable to consent) * Religious or other prohibitive reason for not receiving blood transfusion * History of allergy to epsilon-aminocaproic acid or tranexamic acid * Pregnant or breast-feeding (if applicable) * The participation in another clinical or device trial that would affect the patient's coagulation profile * Cardiac or cardiopulmonary transplantation procedure * Any history of stroke and/or non-coronary thrombotic disorders (DVT, PE) * Clinical signs consistent with non-coronary thrombotic disease * Known congenital deficiency of Protein C, Protein S, Antithrombin and homozygous Factor V Leiden * Known congenital bleeding disorders * Weight \< 50 kg * Weight \> 150 kg * Acute renal failure or creatinine \> 2.0 mg/dL * Current surgery including any implantable ventricular assist device requiring CPB including ECMO (extracorpeal membrane oxygenation) * Current surgery including the aortic arch and/or descending thoracic aorta * Any changes to the planned surgery, which result int he patient not requiring CPB or meeting
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Chest Tube Drainage | 4 hours, 8 hours, 12 hours, 24 hours | Chest tube drainage are collected from the nursing records, every 4th hourly the amount fluid collected is reported in the collection sheets. |
| Median Amount of Blood Products Used | 24 hours after surgery | Four types of blood products may be given through blood transfusions: whole blood, red blood cells, platelets, and plasma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diagnosis of Myocardial Infarction Post-operation | Within 30 days after surgery | Confirmed diagnosis of myocardial infraction and hospitalization for the same within 30 days after the surgery |
| Number of Participants Who Have Confirmed Diagnosis of Respiratory Arrest | Within 30 days after surgery | Confirmed diagnosis of respiratory arrest and hospitalization for the same within 30 days after the surgery |
| Number of Participants With Confirmed Diagnosis of Stroke | Within 30 days after surgery | Confirmed diagnosis of stroke and hospitalization for the same within 30 days after the surgery |
| Diagnosis of Renal Dysfunction Post-operation | Within 30 days after surgery | Confirmed diagnosis of renal dysfunction and hospitalization for the same within 30 days after the surgery |
| Number of Participants With Confirmed Diagnosis of Seizure | Within 30 days after surgery | Confirmed diagnosis of seizure and hospitalization for the same within 30 days after the surgery |
| Reoperation | Within 30 days after surgery | Confirmed diagnosis of reopeartion and hospitalization for the same within 30 days after the surgery |
| Mortality Within 30 Days Post-operation | Within 30 days after surgery | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| Patient Demographics | Baseline | Measurements taken as a composite. BMI, Sex, Age are to be determined to ensure that the subjects' characteristics were comparable between the Epsilon-aminocaproic Acid and Tranexamic Acid groups. |
| Type of Surgery | Intraoperative | — |
| Intraoperative Characteristics | Intraoperative | Measurements are taken as a composite to determine that the subjects' characteristics are comparable between the Epsilon-aminocaproic Acid and Tranexamic Acid groups. Measurements include temperature, Heparin dose, protamine given, time of surgery, time of cardiopulmonary bypass, and aortic clamp time. |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Epsilon-aminocaproic Acid (EACA) Epsilon-aminocaproic acid administered following anesthetic induction: EACA was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr.
Epsilon-aminocaproic acid administered: Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin. | 56 |
| Tranexamic Acid (TA) Tranexamic Acid administered following induction: TA was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion.
Tranexamic Acid administered: Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin. | 58 |
| Total | 114 |
Baseline characteristics
| Characteristic | Epsilon-aminocaproic Acid (EACA) | Tranexamic Acid (TA) | Total |
|---|---|---|---|
| Age, Continuous | 64 years | 65 years | 64 years |
| Region of Enrollment United States | 56 Participants | 58 Participants | 114 Participants |
| Sex/Gender, Customized Female | 19 Participants | 28 Participants | 47 Participants |
| Sex/Gender, Customized Male | 37 Participants | 30 Participants | 67 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 56 | 1 / 58 |
| other Total, other adverse events | 0 / 56 | 0 / 58 |
| serious Total, serious adverse events | 20 / 56 | 14 / 58 |
Outcome results
Chest Tube Drainage
Chest tube drainage are collected from the nursing records, every 4th hourly the amount fluid collected is reported in the collection sheets.
Time frame: 4 hours, 8 hours, 12 hours, 24 hours
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Epsilon-aminocaproic Acid (EACA) | Chest Tube Drainage | 4 hr | 200 mL | Standard Deviation 375 |
| Epsilon-aminocaproic Acid (EACA) | Chest Tube Drainage | 8 hr | 375 mL | Standard Deviation 550 |
| Epsilon-aminocaproic Acid (EACA) | Chest Tube Drainage | 12 hr | 425 mL | Standard Deviation 750 |
| Epsilon-aminocaproic Acid (EACA) | Chest Tube Drainage | 24 hr | 700 mL | Standard Deviation 1100 |
| Tranexamic Acid (TA) | Chest Tube Drainage | 8 hr | 400 mL | Standard Deviation 675 |
| Tranexamic Acid (TA) | Chest Tube Drainage | 24 hr | 800 mL | Standard Deviation 1225 |
| Tranexamic Acid (TA) | Chest Tube Drainage | 4 hr | 225 mL | Standard Deviation 400 |
| Tranexamic Acid (TA) | Chest Tube Drainage | 12 hr | 500 mL | Standard Deviation 825 |
Median Amount of Blood Products Used
Four types of blood products may be given through blood transfusions: whole blood, red blood cells, platelets, and plasma
Time frame: 24 hours after surgery
| Arm | Measure | Value (MEDIAN) | Dispersion |
|---|---|---|---|
| Epsilon-aminocaproic Acid (EACA) | Median Amount of Blood Products Used | .59 L | Standard Deviation 1.3 |
| Tranexamic Acid (TA) | Median Amount of Blood Products Used | 1.20 L | Standard Deviation 2.2 |
Diagnosis of Myocardial Infarction Post-operation
Confirmed diagnosis of myocardial infraction and hospitalization for the same within 30 days after the surgery
Time frame: Within 30 days after surgery
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Epsilon-aminocaproic Acid (EACA) | Diagnosis of Myocardial Infarction Post-operation | 1 Participants |
| Tranexamic Acid (TA) | Diagnosis of Myocardial Infarction Post-operation | 1 Participants |
Diagnosis of Renal Dysfunction Post-operation
Confirmed diagnosis of renal dysfunction and hospitalization for the same within 30 days after the surgery
Time frame: Within 30 days after surgery
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Epsilon-aminocaproic Acid (EACA) | Diagnosis of Renal Dysfunction Post-operation | 3 Participants |
| Tranexamic Acid (TA) | Diagnosis of Renal Dysfunction Post-operation | 2 Participants |
Mortality Within 30 Days Post-operation
Time frame: Within 30 days after surgery
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Epsilon-aminocaproic Acid (EACA) | Mortality Within 30 Days Post-operation | 1 Participants |
| Tranexamic Acid (TA) | Mortality Within 30 Days Post-operation | 1 Participants |
Number of Participants Who Have Confirmed Diagnosis of Respiratory Arrest
Confirmed diagnosis of respiratory arrest and hospitalization for the same within 30 days after the surgery
Time frame: Within 30 days after surgery
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Epsilon-aminocaproic Acid (EACA) | Number of Participants Who Have Confirmed Diagnosis of Respiratory Arrest | 11 Participants |
| Tranexamic Acid (TA) | Number of Participants Who Have Confirmed Diagnosis of Respiratory Arrest | 5 Participants |
Number of Participants With Confirmed Diagnosis of Seizure
Confirmed diagnosis of seizure and hospitalization for the same within 30 days after the surgery
Time frame: Within 30 days after surgery
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Epsilon-aminocaproic Acid (EACA) | Number of Participants With Confirmed Diagnosis of Seizure | 0 Participants |
| Tranexamic Acid (TA) | Number of Participants With Confirmed Diagnosis of Seizure | 0 Participants |
Number of Participants With Confirmed Diagnosis of Stroke
Confirmed diagnosis of stroke and hospitalization for the same within 30 days after the surgery
Time frame: Within 30 days after surgery
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Epsilon-aminocaproic Acid (EACA) | Number of Participants With Confirmed Diagnosis of Stroke | 2 Participants |
| Tranexamic Acid (TA) | Number of Participants With Confirmed Diagnosis of Stroke | 2 Participants |
Reoperation
Confirmed diagnosis of reopeartion and hospitalization for the same within 30 days after the surgery
Time frame: Within 30 days after surgery
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Epsilon-aminocaproic Acid (EACA) | Reoperation | 3 Participants |
| Tranexamic Acid (TA) | Reoperation | 4 Participants |
Intraoperative Characteristics
Measurements are taken as a composite to determine that the subjects' characteristics are comparable between the Epsilon-aminocaproic Acid and Tranexamic Acid groups. Measurements include temperature, Heparin dose, protamine given, time of surgery, time of cardiopulmonary bypass, and aortic clamp time.
Time frame: Intraoperative
Patient Demographics
Measurements taken as a composite. BMI, Sex, Age are to be determined to ensure that the subjects' characteristics were comparable between the Epsilon-aminocaproic Acid and Tranexamic Acid groups.
Time frame: Baseline
Type of Surgery
Time frame: Intraoperative